BIOS Neural Data & AI Platform
Proprietary neural interface and AI platform for real-time neural data measurement and analysis
Platform · HybridCompany source
Company profile
About BIOS Health
BIOS Health is a pioneer in AI-driven precision medicine for the nervous system, founded in 2015 by Cambridge University graduates Emil Hewage (computational neuroscientist) and Oliver Armitage (biomechanical engineer). The company has developed proprietary neural interfaces and AI platforms that can read and write the body's neural data in real-time, creating what they call a 'programming language' for the nervous system. BIOS's technology platform transforms neural data into actionable insights to deliver more precise therapies across both bioelectronic and molecular medicine. Their flagship product, BIOS NeuroTune, is an AI co-pilot that personalizes neuromodulation device settings in under ten minutes, reducing the typical 12-month dosing optimization period to minutes. The company serves pharmaceutical companies, neuromodulation device makers, academic researchers, and clinical research organizations. BIOS is the core technology partner for the NIH's SPARC program and the $21M REVEAL study—the world's largest clinical study of human neural data involving eight global clinics including Stanford University, Mayo Clinic, and University of Minnesota. The company envisions neural digital therapeutics as the next generation of precision medicine, similar to how DNA sequencing opened genomics. BIOS operates research facilities in Cambridge, UK and Montreal, Canada, with plans for a commercial precision medicine center in Bakersfield, California.
Company description BIOS Health official website
Primary marketClinical Trials & Research
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at BIOS Health?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- cardiovascular diseases
- chronic diseases
- diabetes
- epilepsy
- hypertension
- Parkinson's disease
- rheumatoid arthritis
Who it serves
- Academic researchers
- Clinical research organizations (CROs)
- Clinics
- Neuromodulation device makers
- Pharmaceutical companies
Deployment & integration
Cloud Saas · Hybrid deployment with recorded integration context.
Geographic context
MarketsCanada · Global · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
Closed venture funding round June 2023 with Selvedge Venture, XTX Ventures, Real Ventures, Fifty Years, Y Combinator. Selected as core partner for NIH's $21M REVEAL program in 2023. Secured CA$1.8M funding for Canadian AI collaboration on neurocardiology. Plans announced for state-of-the-art precision medicine center in Bakersfield, California.
Partnerships
Recorded partners
- 8 top clinics and research centres globally
- Mayo Clinic
- NIH REVEAL study
- NIH SPARC program
- Stanford University
- University of Minnesota
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
BIOS NeuroTune
AI co-pilot that personalises neuromodulation device settings in under ten minutes
Software · HybridCompany source
Neural Digital Therapeutics
Software-delivered treatments direct to the nervous system using real-time neural feedback
Software · HybridCompany source
VNS Calibrator Simulation
Simulation tool for exploring dose response curves using real vagus nerve stimulation data
Software · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Does Adding Lateral Extra-Articular Tenodesis Improve Outcomes After Arthroscopic Anterior Cruciate Ligament Reconstruction? A Longitudinal Comparative Study.Journal of orthopaedic case reports · Feb 1, 2026
Using neural biomarkers to personalize dosing of vagus nerve stimulation.Bioelectronic medicine · Jun 17, 2024
Online Bayesian optimization of vagus nerve stimulation.Journal of neural engineering · Apr 2, 2024
Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett's Esophagus.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · Nov 1, 2022
Long-term impact of COVID-19 among maintenance haemodialysis patients.Clinical kidney journal · Feb 1, 2022
Next-Generation Bioelectric Medicine: Harnessing the Therapeutic Potential of Neural Implants.Bioelectricity · Dec 1, 2020
Clinical validation
Clinical-trial records
Intra-articular Administration of Med Device Made of Biological Vegetal Matrix for the Treatment of Knee OsteoarthritisNCT05925595 · Sponsor · COMPLETED
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Dosing optimization time reduced from 12 months to under 10 minutes
For epilepsy patients with Vagus Nerve Stimulator
15x faster discovery than competing platforms
Preclinical therapy discovery
Assesses thousands of unique stimulations in a single trial
Order of magnitude improvement vs most pre-clinical trials
NIH SPARC Program (REVEAL Study)
Powering the world's largest single clinical study of human neural data across 8 global clinics including University of Minnesota, Mayo Clinic, and Stanford University
$21M seminal project over 3 years to create the world's largest dataset of multi-organ responses to bioelectronic stimulation
Epilepsy Patients with Vagus Nerve Stimulators
Reducing time to reach target dose for epilepsy patients with Vagus Nerve Stimulators from 12 months to under 10 minutes
Personalised dosing achieved in under 10 minutes compared to 12 months with traditional methods, reducing the 1 in 4 patients who never reach target dose due to side effects
NIH SPARC VESPA Study
Partnering with eight top clinics and research centres to create the world's largest dataset of multi-organ responses to bioelectronic stimulation
15x faster discovery than competing platforms
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
06 · Company updates
Updates from BIOS Health
Recent articles published on BIOS Health's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Clinical Trials & Research
Companies using AI to optimize clinical trial design, accelerate patient recruitment, match patients to trials, predict trial outcomes, or improve clinical research efficiency. Includes patient enrollment and screening platforms, AI-powered trial matching, and tools that reduce the time and cost of bringing new treatments to market.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.